The effects of fenofibrate on cardiac functio

Not Applicable

• Conditions: coronary artery disease,dyslipidemia.; Atherosclerotic heart disease,Pure hypercholesterolaemia,Pure hyperglyceridaemia,Mixed hyperlipidaemia,Other hyperlipidaemia,Hyperlipidaemia, unspecified; 125.1,E78.

• Registration Number: IRCT2012122411865N1
• Lead Sponsor: Baqiatallah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

The inclusion criteria:patients diagnosed with constant CAD with positive Exercise Test Time (ETT); Total Cholesterol (TC)=200 mg/dl; Triglyceride (TG)=250 mg/dl; Low Density lipoprotein (LDL)=100 mg/dl; normal liver function test
The inclusion criteria:patients diagnosed with constant CAD with positive Exercise Test Time (ETT); Total Cholesterol (TC)=200 mg/dl; Triglyceride (TG)=250 mg/dl; Low Density lipoprotein (LDL)=100 mg/dl; normal liver function test

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Exercise test. Timepoint: before and after intervention. Method of measurement: treadmill and changes in ECG.;Lipid profile. Timepoint: before intervention,1.5 month.3 month and after intervention(12month). Method of measurement: blood test.

Secondary Outcome Measures

Name	Time	Method
iver enzymes. Timepoint: before intervention,1.5 month,3 month,after intervention(12month). Method of measurement: blood test.;ECG. Timepoint: before and after intervention(12month). Method of measurement: electrocardiography device.